Jump to content
RemedySpot.com

Re: new studies

Rate this topic


Guest guest

Recommended Posts

Guest guest

Hi Lee;

I don't know of anyone participating in ongoing " Humira (Adalimumab) "

studies. I think that " Humira (Adalimumab) " is similar in its mode of

action to " Etanercept (Enbrel) " . They both target tumor necrosis

factor alpha. Pilot studies with " Etanercept " did not show anything

too excting (see below), but this is not to say that " Humira " will be

without effect in PSC?

______________________

Dig Dis Sci. 2004 Jan;49(1):1-4.

A pilot study of etanercept in the treatment of primary sclerosing

cholangitis.

Epstein MP, Kaplan MM.

Division of Gastroenterology, Tufts New England Medical Center,

Boston, Massachusetts 02111, USA.

There is no effective medical treatment for primary sclerosing

cholangitis (PSC), a chronic cholestatic liver disease that usually

progresses to cirrhosis and liver failure. The aim of this study was

to determine the safety and efficacy of etanercept, an inhibitor of

tumor necrosis factor, in the treatment of PSC. Ten patients with

clinically active PSC were studied. All had elevated serum alkaline

phosphatase levels, cholangiograms that were diagnostic of PSC, and

liver histology consistent with PSC. Five patients had elevated serum

bilirubin levels, five had pruritus, eight had failed to respond to

ursodiol and/or methotrexate, and six had rapidly recurring dominant

bile duct strictures. Patients were to receive etanercept, 25 mg

subcutaneously twice weekly, for 6 months if there were no side

effects and for 1 year if there was evidence of efficacy after 6

months. Biochemical tests of liver function did not improve in any

patient. Mean serum bilirubin levels increased significantly, from

2.0 to 3.6 mg/dl (P = 0.026). Two of the five patients with pruritus

had resolution of pruritus during treatment with etanercept,

recurrence when etanercept was stopped, and resolution when it was

restarted, although there was little change in liver enzymes or

bilirubin levels. There was no decrease in the rate of stricture

formation and there were no side effects. Etanercept, at the dosage

used, was well tolerated but not effective in the treatment of PSC.

It may be helpful in treating pruritus due to cholestasis.

Publication Types:

Clinical Trial

PMID: 14992426

______________________

Perhaps these kinds of medications will be more important initially

in treating inflammatory bowel disease, as described in the following

article:

http://www.uchospitals.edu/news/2004/20040521-ibd.php

Best regards, and I hope that your son is doing well and responding

to the asacol.

Dave

(father of (19); PSC 07/03; UC 08/03)

> is anyone out there with PSC participating in Humira studies? I

heard

> that they might be testing it.

> Lee

Link to comment
Share on other sites

Guest guest

Thanks Dave, I read the article which was just as you said. Not

exciting. Oh well, on to the next one.

Lee

> Hi Lee;

>

> I don't know of anyone participating in ongoing " Humira (Adalimumab) "

> studies. I think that " Humira (Adalimumab) " is similar in its mode of

> action to " Etanercept (Enbrel) " . They both target tumor necrosis

> factor alpha. Pilot studies with " Etanercept " did not show anything

> too excting (see below), but this is not to say that " Humira " will be

> without effect in PSC?

>

> ______

Link to comment
Share on other sites

Join the conversation

You are posting as a guest. If you have an account, sign in now to post with your account.
Note: Your post will require moderator approval before it will be visible.

Guest
Reply to this topic...

×   Pasted as rich text.   Paste as plain text instead

  Only 75 emoji are allowed.

×   Your link has been automatically embedded.   Display as a link instead

×   Your previous content has been restored.   Clear editor

×   You cannot paste images directly. Upload or insert images from URL.

Loading...
×
×
  • Create New...